# US 2024/0254187 A1 · Dual-function protein for lipid and blood glucose regulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254187 A1
- Document ID: US20240254187A1
- Status: Published application
- Kind: A1
- Application number: 18/624,726
- Filed: 2024-04-02
- Published: 2024-08-01
- Earliest claimed: 2020-05-27
- Assignees: Ampsource Biopharma Shanghai Inc.
- Applicants: Ampsource Biopharma Shanghai Inc.
- Inventors: Zhao DONG; Chi ZHOU; Xiong FENG; Jiyu ZHANG; Shixiang JIA; Qiang LI
- Web page: https://patentgrep.com/patent/US20240254187A1

## CPC

- C07K 14/605: Glucagons
- C07K 14/50: Fibroblast growth factor [FGF]
- C12N 15/85: for animal cells
- A01K 2227/105: Murine
- A01K 2267/0362: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.

## Claims

### Claim at position 1

-26. (canceled)

### Claim 27

A method of treatment of one or more diseases, comprising administering to a person suffering from at least one of said diseases an effective amount of one or more dual-function proteins;
wherein the one or more dual-function proteins are selected from a dual-function protein comprising the amino acid sequence of SEQ ID NO: 13 and a dual-function protein comprising the amino acid sequence of SEQ ID NO: 15; and
wherein the disease is selected from obesity, type 1 diabetes, pancreatitis, dyslipidemia, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, insulin resistance, hyperinsulinemia, metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, nephropathy, diabetic complication, neuropathy, gastroparesis, and symptoms associated with the severe inactivation mutations of insulin receptor.

### Claim 28

(canceled)

### Claim 29

A method of treatment of one or more diseases, comprising administering to a person suffering from at least one of said diseases an effective amount of a pharmaceutical composition comprising a dual-function protein comprising the amino acid sequence of SEQ ID NO: 13 and/or a dual-function protein comprising the amino acid sequence of SEQ ID NO: 15;
wherein the disease is selected from obesity, type 1 diabetes, pancreatitis, dyslipidemia, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, insulin resistance, hyperinsulinemia, metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, nephropathy, diabetic complication, neuropathy, gastroparesis, and symptoms associated with the severe inactivation mutations of insulin receptor.

### Claim 30

(canceled)

### Claim 31 (depends on 27)

The method of treatment of claim 27, comprising administering to the person suffering from the at least one of said diseases an effective amount of the dual-function protein comprising the amino acid sequence of SEQ ID NO: 13.

### Claim 32 (depends on 27)

The method of treatment of claim 27, comprising administering to the person suffering from the at least one of said diseases an effective amount of the dual-function protein comprising the amino acid sequence of SEQ ID NO: 15.

### Claim 33 (depends on 27)

The method of treatment of claim 27, wherein the disease is selected from obesity, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nephropathy.

### Claim 34 (depends on 31)

The method of treatment of claim 31, wherein the disease is selected from obesity, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nephropathy.

### Claim 35 (depends on 32)

The method of treatment of claim 32, wherein the disease is selected from obesity, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nephropathy.

### Claim 36 (depends on 29)

The method of treatment of claim 29, wherein the pharmaceutical composition comprises the dual-function protein comprising the amino acid sequence of SEQ ID NO: 13.

### Claim 37 (depends on 29)

The method of treatment of claim 29, wherein the pharmaceutical composition comprises the dual-function protein comprising the amino acid sequence of SEQ ID NO: 15.

### Claim 38 (depends on 29)

The method of treatment of claim 29, wherein the disease is selected from obesity, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nephropathy.

### Claim 39 (depends on 36)

The method of treatment of claim 36, wherein the disease is selected from obesity, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nephropathy.

### Claim 40 (depends on 37)

The method of treatment of claim 37, wherein the disease is selected from obesity, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and nephropathy.

### Claim 41 (depends on 27)

The method of treatment of claim 27, wherein the one or more dual-function proteins are administered subcutaneously.

### Claim 42 (depends on 29)

The method of treatment of claim 29, wherein the pharmaceutical composition is administered subcutaneously.

### Claim 43 (depends on 27)

The method of treatment of claim 27, further comprising evaluating the effect of the treatment after administering the one or more dual-function proteins to the person.

### Claim 44 (depends on 29)

The method of treatment of claim 29, further comprising evaluating the effect of the treatment after administering the pharmaceutical composition to the person.
